Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, successfully passed resolutions at its 2024 Annual General Meeting. The company is advancing its lead asset, ATH434, in Phase 2 clinical trials targeting Multiple System Atrophy, while also expanding its drug discovery platform. Based in Melbourne and San Francisco, Alterity aims to revolutionize treatments for Parkinsonian disorders.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
